Ipsen SA - Company Profile

All the data and insights you need on Ipsen SA in one report.

$295

Buy Report View Sample

Save hours of research time and resources with
our up-to-date Ipsen SA Strategy Report
Understand Ipsen SA position in the market,
performance and strategic initiatives.
Gain competitive edge and increase your
chances of success

Ipsen SA: Premium Databases

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 40+ results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	06 Jun 2019	Lorem
ICON is CRO in Regeneron’s garetosmab Phase II fibrodysplasia ossificans progressiva study, source says	26 Feb 2019	Jennifer C. Smith-Parker
Clementia’s, Regeneron’s FOP studies trigger mixed expert feedback on clinical relevance of bone surrogate primary endpoint	20 Feb 2019	Jennifer C. Smith-Parker
Tyme’s potential pivotal SM-88 trial in third-line pancreatic cancer needs BSC or placebo comparator with 400 patients, OS and PFS endpoints valuable for clinical relevance, experts say	12 Feb 2019	Reynald Castaneda

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of Ipsen SA and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer